Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 40 P11 | DOI: 10.1530/endoabs.40.P11

ESEBEC2016 Poster Presentations (1) (25 abstracts)

Acromegaly caused by hepatic metastasis of a pulmonary neuroendocrine tumor

Eduarda Resende , Pedro Gouveia , Maritza Sá , Margarida Ferreira & Silvestre Abreu

Serviço de Endocrinologia, Hospital Central do Funchal, Funchal, Portugal.

Introduction: Acromegaly is usually caused by a pituitary adenoma; ectopic or eutopic secretion of GHRH is a rare condition, responsible for <1% of the cases. Ectopic secretion of GH itself is even rarer.

Case report: A 34-year-old woman was referred to the Endocrine Clinic with a multinodular goiter. However, on physical examination there were some physical signs of acromegaly: coarsening of facial features, protusion of the lower jaw and thick, oily skin. In her past medical history there was a right lung lower lobectomy with a histologic diagnosis of a typical carcinoid. Laboratory investigation showed a seric concentration of IGF1 of 826 ng/ml (136–449), and a fine-needle aspiration of a thyroid nodule revelead a cytologic diagnosis suspicious of papillary carcinoma. A random GH level was 7.7 ng/dl, and after a 75 g oral glucose load the GH was 9.4 ng/dl. The pituitary MRI, however, did not show a tumor, but its dimensions were increased, which raised the possibility of ectopic acromegaly. Since our patient had an history of a pulmonary carcinoid, it was asked a chest and abdominal CT, which showed ‘eight nodules in the liver, highly suspicious of metastatic involvement by the primary neuroendocrine tumor’. She had a discrete elevation of chromogranin A and no elevation of 5-hydroxyindoleacetic acid. A Ga68 – PET – DOTANOC revealed an increased captation in the hepatic lesions, and a biopsy was performed, confirming the neuroendocrine origin of the metastasis; immunohistochemical staining was positive for GH and negative for GHRH (Cohen antibody, 1:2000, automated method). The patient was initiated on monthly intramuscular octreotide (20 mg), and was submitted to radioembolization of the hepatic lesions, with a notable reduction in the size of the metastasis. A total thyroidectomy confirmed the diagnosis of papillary thyroid carcinoma, but with no indication for radioiodine ablation. Posteriorly it was asked a plasmatic determination of GHRH, which was negative (<60 ng/dl). At the moment the IGF1 levels are in the normal range and the GH level is <1 ng/dl, and the size of the hepatic metastasis is stable.

Clinical lessions: The diagnosis of ectopic secretion causing acromegaly may be suspected in any case of clinically suspected and biochemically proven acromegaly with no pituitary adenoma. However, this case has many peculiarities: in spite of the hyperplasia of the pituitary (which is suspicious of GHRH hypersecretion), the immunohistochemical staining was negative for this hormone and positive for GH; it is important to note that the biopsy sample was very small and the expression of GHRH is usually focal. So, to clarify this situation it was asked a determination of plasmatic GHRH, which is the gold-standard for the diagnosis: it was negative (even when the patient is under somatostatin analogues this value is positive in cases of ectopic secretion of GHRH). Therefore, it remans the doubt: is this clinical picture caused by ectopic secretion of GH? Or it may be caused by ectopic secretion of a truncated form of GHRH not detectable by radioimmunoassay but with biological activity?

Volume 40

ESE Basic Endocrinology Course on Endocrine and Neuroendocrine Cancer 2016

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.